In primary SjS, this speculation is particularly apt, as BAFF levels are known to be elevated [41] and to increase after rituximab therapy in this disease [42,43], including the current subject cohort and in SjS2 in particular [15]. The gene discussed is TNFSF13B; the disease is Stüve-Wiedemann syndrome 1.